<Header>
<FileStats>
    <FileName>20161102_10-K-A_edgar_data_1369868_0001144204-16-131123_1.txt</FileName>
    <GrossFileSize>93791</GrossFileSize>
    <NetFileSize>30912</NetFileSize>
    <ASCII_Embedded_Chars>0</ASCII_Embedded_Chars>
    <HTML_Chars>54545</HTML_Chars>
    <XBRL_Chars>0</XBRL_Chars>
    <XML_Chars>0</XML_Chars>
    <N_Tables>2</N_Tables>
    <N_Exhibits>2</N_Exhibits>
</FileStats>
<SEC-Header>
0001144204-16-131123.hdr.sgml : 20161102
<ACCEPTANCE-DATETIME>20161102160643
ACCESSION NUMBER:		0001144204-16-131123
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20081231
FILED AS OF DATE:		20161102
DATE AS OF CHANGE:		20161102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			China Biologic Products, Inc.
		CENTRAL INDEX KEY:			0001369868
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				752308816
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34566
		FILM NUMBER:		161967853

	BUSINESS ADDRESS:	
		STREET 1:		18TH FL, JIALONG INTERNATIONALBUILDING
		STREET 2:		19 CHAOYANG PARK ROAD, CHAOYANG DISTRICT
		CITY:			BEIJING
		STATE:			F4
		ZIP:			100125
		BUSINESS PHONE:		86-10-6598-3111

	MAIL ADDRESS:	
		STREET 1:		18TH FL, JIALONG INTERNATIONALBUILDING
		STREET 2:		19 CHAOYANG PARK ROAD, CHAOYANG DISTRICT
		CITY:			BEIJING
		STATE:			F4
		ZIP:			100125

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GRC Holdings, Inc.
		DATE OF NAME CHANGE:	20060721

</SEC-Header>
</Header>

 0001144204-16-131123.txt : 20161102

10-K/A
 1
 v451981_10ka.htm
 FORM 10-K/A

UNITED STATES  

  SECURITIES AND EXCHANGE COMMISSION  

 Washington, D.C. 20549 

FORM 10-K/A  

  (Amendment No. 1)  

Q      ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934           

 For the fiscal year ended:  December
31, 2008  

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   

 For the transition period from ____________
to _____________ 

Commission File No. 000-53208  

CHINA BIOLOGIC PRODUCTS, INC.   

(Exact name of registrant as specified in
its charter) 

DELAWARE    
        75-2308816     
 
      (State or other jurisdiction of incorporation or organization)  
      (I.R.S. Employer Identification No.)   

No. 14 East Hushan Road, 
         Taian City, Shandong 
         People's Republic of China 271000 
         -------------------------------------------------------------   
 
      (Address of principal executive offices)   
 
 (+86) 538-620-2306 

 -------------------------------------------------------------- 

 (Registrant s telephone number, including
area code) 

 Securities registered pursuant to Section 12(b) of the Exchange
Act: 

Title of each class    
        Name of each exchange on which registered     
 
      None  
      None   
 
 Securities registered pursuant to Section 12(g) of the Exchange
Act: Common Stock, par value $0.0001 per share 

Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.   Yes       
No   Q  

Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.   Yes       
No   Q  

Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.   Yes   Q    
No      

Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be
contained, to the best of registrant s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K.     Q  

Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of  large accelerated
filer,   accelerated filer  and  smaller reporting company  in Rule 12b-2 of the Exchange Act. (Check
one) 

Large accelerated filer       
      Non-accelerated filer       
      Accelerated filer        
      Smaller reporting company   Q   

(Do not check if smaller reporting company)  

Indicate
by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes       
No   Q  

As of June 30, 2008 (the last business day of the registrant s
most recently completed second fiscal quarter), the aggregate market value of the shares of the Registrant s common stock
held by non-affiliates (based upon the closing price of such shares as quoted on the Electronic Bulletin Board maintained by the
National Association of Securities Dealers, Inc.) was approximately $6.17 million. Shares of the Registrant s common stock
held by each executive officer and director and each by each person who owns 10 percent or more of the outstanding common stock
have been excluded in that such persons may be deemed to be affiliates of the Registrant. This determination of affiliate status
is not necessarily a conclusive determination for other purposes. There were a total of 21,434,942 shares of the registrant s
common stock outstanding as of March 31, 2009. 

Documents Incorporated by Reference:  

None. 

Table
of Contents   

E xplanatory
    Note   
     3  
 
      ITEM 5. MARKET FOR REGISTRANT S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.  
     4  
 
      ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.  
     5  
 
      ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.  
     5  
 
      SIGNATURES  
     7  
 
      EXHIBIT INDEX  
     9  

2   

Explanatory
Note  

We are filing this Amendment No. 1
(this  Amendment ) to our annual report on Form 10-K for the fiscal year ended December 31, 2008 (the
 Original Form 10-K ), which was originally filed with the Securities and Exchange Commission on March 31, 2009,
for the sole purpose of revising information set forth in the sections captioned  Securities Authorized for Issuance
under Equity Compensation Plans  under Item 5 and Item 12 of the Original Form 10-K provided pursuant to Item 201(d) of
Regulation S-K. This Amendment does not affect the information in the other sections under Item 5 or Item 12 of the Original
Form 10-K. 

In addition, we are also filing new certifications
by our principal executive officer and principal financial officer as exhibits to this Amendment pursuant to Rule 13a-14(a) of
the Securities Exchange Act of 1934, as amended. Therefore, this Amendment also updates the list of exhibits under Item 15 of the
Original Form 10-K by incorporating such new certifications filed as Exhibits 31.1 and 31.2 hereto. We are not including certifications
pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) as no financial statements are being
filed with this Amendment. 

No other changes have been made to the
Original Form 10-K. This Amendment does not reflect events that have occurred after the filing of the Original Form 10-K, or modify
or update the disclosures presented therein, except to reflect the amendment described above. 

3   

PART II  

ITEM 5. MARKET FOR REGISTRANT S
COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES. 

Securities Authorized for Issuance under
Equity Compensation Plans   

See  Item 12. Security Ownership
of Certain Beneficial Owners and Management and Related Stockholder Matters Securities Authorized for Issuance under Equity
Compensation Plans,  which is incorporated herein by reference. 

4   

PART III  

ITEM 12. SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS. 

Securities Authorized for Issuance under
Equity Compensation Plans   

The following table includes the information
as of December 31, 2008 for each category of our equity compensation plan: 

Plan category   
     
          Number
        of securities 
        to be issued upon 
        exercise of 
        outstanding options, 
        warrants and rights 
        (a)    
     
          Weighted-average  
         exercise price of  
         outstanding options,  
         warrants and rights  
         (b)   
     
          Number
        of securities 
        remaining available for 
        future issuance under 
        equity compensation 
        plans (excluding 
        securities reflected in 
        column (a)) 
        (c)    
 
      Equity compensation plans approved by security holders (1)   
      997,500  
      4.00  
      4,002,500   
 
      Equity compensation plans not approved by security holders   
      -  
      -  
      -   
 
       Total   
      997,500  
      4.00  
      4,002,500   

(1)  Our board of directors adopted our 2008 Equity Incentive Plan, or the 2008 Plan, on May 9, 2008
and shortly thereafter sought and obtained approval by written consent from the holders of a majority of our then outstanding shares,
which we believed was effective approval under the Delaware General Corporation Law. However, in response to an SEC comment in
2010, the disclosure in the foregoing table was revised for presently unknown reasons to reflect that the 2008 Plan was not approved
by our stockholders. We have recently reviewed our records relating to the 2008 approval of the 2008 Plan. While the 2008 Plan
was approved by stockholders holding a majority of our stock acting by written consent, and therefore we believe that the 2008
Plan was approved, in connection with the recent review of our records, we recognized that there may be some technical defects
in the manner in which the approval was obtained in 2008. We are in the process of collecting additional information and will continue
our analysis of whether such stockholder approval complied with all the technical requirements of Delaware law and will take appropriate
steps in light of that assessment.   

The 2008 Plan provides for grants of stock
options, stock appreciation rights, performance units, restricted stock, restricted stock units and performance shares. A total
of five million (5,000,000) shares of our common stock may be issued pursuant to the 2008 Plan. The exercise price per share for
the shares to be issued pursuant to an exercise of a stock option will be no less than the fair market value per share on the grant
date, except that, in the case of an incentive stock option granted to a person who holds more than 10% of the total combined voting
power of all classes of our stock or any of our subsidiaries, the exercise price will be no less than 110% of the fair market value
per share on the grant date. No more than an aggregate of 500,000 shares (or for awards denominated in cash, the fair market value
of 5,000,000 shares on the grant date) may be subject to awards under the 2008 Plan to any individual participant in any one fiscal
year. No awards may be granted under the 2008 Plan after May 9, 2018, except that any award granted before then may extend beyond
that date. 

PART IV  

ITEM 15. EXHIBITS, FINANCIAL STATEMENT
SCHEDULES. 

Exhibit List   

The list of exhibits in the Exhibit Index
to this Report is incorporated herein by reference. 

5   

SIGNATURES 

In accordance with section 13 or 15(d)
of the Securities Exchange Act of 1934, the registrant caused this Amendment No.1 to the Annual Report on Form 10-K to be signed
on its behalf by the undersigned, thereto duly authorized individual. 

Date: November 2, 2016. 

CHINA BIOLOGIC PRODUCTS, INC.   

By:
      /s/ David (Xiaoying) Gao                              

David (Xiaoying) Gao   
 Chief Executive Officer  

6   

POWER OF ATTORNEY  

KNOW ALL PERSONS BY THESE PRESENTS, that
each person whose signature appears below constitutes and appoints David (Xiaoying) Gao and Ming Yang, jointly and severally, as
his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his
name, place and stead, in any and all capacities, to sign this Amendment No.1 to the Annual Report on Form 10-K and to file the
same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting
unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary
to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their
substitute or substitutes, may lawfully do or cause to be done by virtue hereof. 

Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the
registrant in the capacities and on the dates indicated . 

Signature  
       
      Title  
      Date   

/s/ David (Xiaoying) Gao  
       
      Chairman and Chief Executive Officer  
      November 1, 2016   
 
      David (Xiaoying) Gao  
       
      (Principal Executive Officer)  

/s/ Ming Yang  
       
      Chief Financial Officer  
      November 1, 2016   
 
      Ming Yang  
       
      (Principal Financial and Accounting Officer )  

/s/ Sean Shao  
       
      Director  
      November 1, 2016   
 
      Sean Shao  

/s/ Joseph Chow  
       
      Director  
      November 1, 2016   
 
      Joseph Chow  

/s/ Yungang Lu  
       
      Director  
      November 1, 2016   
 
      Yungang Lu  

/s/ David Hui Li  
       
      Director  
      November 1, 2016   
 
      David Hui Li  

/s/ Wenfang Liu  
       
      Director  
      November 1, 2016   
 
      Wenfang Liu  

/s/ Albert (Wai Keung) Yeung  
       
      Director  
      November 1, 2016   
 
      Albert (Wai Keung) Yeung  

Director  

Zhijun Tong  

7   

EXHIBIT INDEX 

Exhibit No.    
       
       Description     

2.1   
       
      Share Exchange Agreement between the Company, Logic Express Limited and the selling stockholders signatory thereto, dated as of July 18, 2006 (incorporated by reference to Exhibit 2 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      3.1   
       
      Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 of the  registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      3.2*  
       
      Amended and Restated By-Laws, adopted on March 31, 2009    
 
      4.1   
       
      Securities Purchase Agreement between the Company, Logic Express Limited, Shandong Taibang Biological Products Co., Ltd., and the selling stockholders and investors signatory thereto, dated as of July 18, 2006 (incorporated by reference to Exhibit 4.1 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      4.2   
       
      Registration Rights Agreement, between the Company and certain investors signatory thereto, dated as of July 18, 2006 (incorporated by reference to Exhibit 4.2 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      4.3   
       
      Form of Stockholder Warrant to purchase Common Stock, dated as of July 19, 2006 (incorporated by reference to Exhibit 4.3 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      4.4   
       
      Lane Warrant, dated as of July 19, 2006 (incorporated by reference to Exhibit 4.4 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      4.5   
       
      Share Escrow Agreement, between the Company, Lane, as investor representative, the Escrow Agent, and the selling stockholders signatory thereto, dated as of July 19, 2006 (incorporated by reference to Exhibit 4.5 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      4.6   
       
      Escrow Agreement, between the Company, the Escrow Agent, and the selling stockholders signatory thereto, dated as of July 19, 2006 (incorporated by reference to Exhibit 4.6 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      4.7   
       
      Amendment No. 1 to the Share Escrow Agreement, between the Company, Lane, as investor representative, the Escrow Agent, and the selling stockholders signatory thereto, dated as of February 16, 2007 (incorporated by reference to Exhibit 4.7 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      4.8   
       
      Amendment No. 2 to Share Escrow Agreement, between the Company, Lane, as investor representative, the Escrow Agent, and the selling stockholders signatory thereto, dated as of March 27, 2007 (incorporated by reference to Exhibit 4.8 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      4.9   
       
      Amendment No. 3 to Share Escrow Agreement, between the Company, Lane, as investor representative, the Escrow Agent, and the selling stockholders signatory thereto, dated as of April 2, 2007 (incorporated by reference to Exhibit 4.9 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      4.10   
       
      Amendment No. 4 to Share Escrow Agreement, between the Company, Lane, as investor representative, the Escrow Agent, and the selling stockholders signatory thereto, dated as of May 9, 2007 (incorporated by reference to Exhibit 4.10 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      4.11   
       
      Amendment No. 1 to Securities Purchase Agreement, between the Company, Logic Express Limited, Shandong Taibang Biological Products Co., Ltd. and the selling stockholders and investors signatory thereto, dated as of February 16, 2007 (incorporated by reference to Exhibit 4.11 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      4.12   
       
      Amendment No. 2 to Securities Purchase Agreement, between the Company, Logic Express Limited, Shandong Taibang Biological Products Co., Ltd. and the selling stockholders and investors signatory thereto, dated as of March 27, 2007 (incorporated by reference to Exhibit 4.12 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    

8   

4.13   
       
      Amendment No. 3 to Securities Purchase Agreement, between the Company, Logic Express Limited, Shandong Taibang Biological Products Co., Ltd. and the selling stockholders and investors signatory thereto, dated as of April 2, 2007 (incorporated by reference to Exhibit 4.13 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      4.14   
       
      Amendment No. 4 to Securities Purchase Agreement, between the Company, Logic Express Limited, Shandong Taibang Biological Products Co., Ltd. and the selling stockholders and investors signatory thereto, dated as of May 9, 2007 (incorporated by reference to Exhibit 4.14 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      4.15   
       
      Amendment No. 5 to Securities Purchase Agreement, between the Company and investors signatory thereto, dated as of August 20, 2007 (incorporated by reference to Exhibit 4.15 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      10.1.   
       
      China Biologic Products, Inc. 2008 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of the current report on Form 8-K, filed by the Company on May 13, 2008)    
 
      10.2.   
       
      Form of Stock Option Award Agreement of China Biologic Products, Inc. (incorporated by reference to Exhibit 10.5 of the current report on Form 8-K, filed by the Company on May 13, 2008)    
 
      10.3.   
       
      Group Secondment Agreement, dated October 28, 2002, between Shandong Taibang Biological Products Co., Ltd. and the Shandong Institute (English Translation) (incorporated by reference to Exhibit 10.1 of the registration statement on Form SB-2/A, filed by the Company on December 3, 2007)    
 
      10.4.   
       
      Amended and Restated Joint Venture Agreement, between Logic Express Limited and the Shandong Institute, dated as of March 12, 2006 (English Translation) (incorporated by reference to Exhibit 10.2 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      10.5.   
       
      Letter of Intent for Equity Transfer, between Logic Express Limited and the Shandong Institute, dated as of June 10, 2006 (English Translation) (incorporated by reference to Exhibit 10.3 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      10.6.   
       
      Raw Plasma Supply Agreement, between Shandong Taibang Biological Products Co., Ltd. and Qihei Plasma Collection Station, dated as of December 30, 2005 (English Translation) (incorporated by reference to Exhibit 10.4 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      10.7.   
       
      Raw Plasma Supply Agreement, between Shandong Taibang Biological Products Co., Ltd. and the Xiajin Plasma Collection Station, dated as of December 30, 2005 (English Translation) (incorporated by reference to Exhibit 10.5 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    
 
      10.8.   
       
      Raw Plasma Supply Agreement, between Shandong Taibang and the Zhangqiu Plasma Collection Station, dated as of December 30, 2005 (English Translation) (incorporated by reference to Exhibit 10.6 of the registration statement on Form SB-2, filed by the Company on September 5, 2007)    

9   

10.9.   
       
      Plasma Processing Agreement, between Shandong Taibang Biological Products Co., Ltd. and Qi He An Tai Plasma Collection Co., Ltd., dated as of January 2, 1007 (English Translation) (incorporated by reference to Exhibit 10.9 of the registration statement on Form SB-2/A, filed by the Company on December 3, 2007)    
 
      10.10.   
       
      Plasma Processing Agreement, between Shandong Taibang Biological Products Co., Ltd. and the Xia Jin An Tai Plasma Collection Co., Ltd., dated as of January 2, 2007 (English Translation) (incorporated by reference to Exhibit 10.10 of the registration statement on Form SB-2/A, filed by the Company on December 3, 2007)    
 
      10.11.   
       
      Plasma Processing Agreement, between Shandong Taibang Biological Products Co., Ltd. and the Zhang Qiu An Tai Plasma Collection Co., Ltd., dated as of January 2, 2007 (English Translation) (incorporated by reference to Exhibit 10.11 of the registration statement on Form SB-2/A, filed by the Company on December 3, 2007)    
 
      10.12.   
       
      Asset Purchase Agreement, between Zhang Qiu An Tai Plasma Collection Co., Ltd. and Zhang Qiu Plasma Collection Station, dated as of December 31, 2006 (English Translation) (incorporated by reference to Exhibit 10.12 of the registration statement on Form SB-2/A, filed by the Company on December 3, 2007)    
 
      10.13.   
       
      Asset Purchase Agreement, between Guang Xi Huan Jiang Missile Plasma Collection Co., Ltd. and Huan Jiang Maonan Autonomous County Plasma Collection Station, dated as of April 24, 2007 (English Translation) (incorporated by reference to Exhibit 10.13 of the registration statement on Form SB-2/A, filed by the Company on December 3, 2007)    
 
      10.14.   
       
      Asset Purchase Agreement, between Qi He An Tai Plasma Collection Co., Ltd. and Qi He County Plasma Collection Station, dated as of November 9, 2006 (English Translation) (incorporated by reference to Exhibit 10.14 of the registration statement on Form SB-2/A, filed by the Company on December 3, 2007)    
 
      10.15.   
       
      Asset Purchase Agreement, between Xia Jin An Tai Plasma Collection Co., Ltd. and Xia Jin County Plasma Collection Station, dated as of October 20, 2006 (English Translation) (incorporated by reference to Exhibit 10.15 of the registration statement on Form SB-2/A, filed by the Company on December 3, 2007)    
 
      10.16.   
       
      Asset Purchase Agreement, between Liao Cheng An Tai Plasma Collection Co., Ltd. and Yang Gu County Plasma Collection Station, dated as of November 3, 2006 (English Translation) (incorporated by reference to Exhibit 10.16 of the registration statement on Form SB-2/A, filed by the Company on December 3, 2007)    
 
      10.17.   
       
      Asset Purchase Agreement, between Fang Cheng Plasma Collection Co., Ltd. and Fang Cheng Plasma Company, dated as of April 30, 2007 (English Translation) (incorporated by reference to Exhibit 10.21 of the registration statement on Form SB-2/A, filed by the Company on December 3, 2007)    
 
      10.18.   
       
      Asset Purchase Agreement, between He Ze An Tai Plasma Collection Co., Ltd and Yun Cheng County Plasma Collection Station, dated as of December 15, 2006 (English Translation) (incorporated by reference to Exhibit 10.22 of the registration statement on Form SB-2/A, filed by the Company on December 3, 2007)    
 
      10.19.   
       
      Raw Plasma Supply Agreement, between Shandong Taibang Biological Products Co., Ltd. and Liao Cheng Tiantan Plasma Collection Co. Ltd., dated as of November 1, 2007 (English Translation) (incorporated by reference to Exhibit 10.23 of the registration statement on Form SB-2/A, filed by the Company on December 28, 2007)    
 
      10.20.   
       
      Asset Purchase Agreement, between Guang Xi Huan Jiang Missile Plasma Collection Co., Ltd. and Huan Jiang Maonan Autonomous County Plasma Collection Station, dated as of August 5, 2007 (English Translation) (incorporated by reference to Exhibit 10.13 of the registration statement on Form SB-2/A, filed by the Company on December 3, 2007)    

10   

10.21.   
       
      Equity Transfer Agreement, dated September 26, 2008, among Logic Express Limited, Chongqing Dalin Biologic Technologies Co., Ltd. and certain shareholders of Chongqing Dalin Biologic Technologies Co., Ltd. (incorporated by reference to Exhibit 10.1 of the current report on Form 8-K, filed by the Company on October 2, 2008)    
 
      10.22.   
       
      Supplemental Agreement, dated November 3, 2008, among Logic Express Limited, Fan Shaowen, as representative of the shareholders of Chongqing Dalin Biologic Technologies Co., Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd. (English Translation) (incorporated by reference to Exhibit 10.2 of the current report on Form 8-K, filed by the Company on November 7, 2008)    
 
      10.23.   
       
      Second Supplemental Agreement, dated November 14, 2008, among Logic Express Limited, Fan Shaowen as representative of the shareholders of Chongqing Dalin Biologic Technologies Co., Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd. (English Translation) (incorporated by reference to exhibit 10.3 of the current report of Form 8-K, filed by the Company on November 20, 2008)    
 
      10.24.   
       
      Amended Equity Transfer Agreement, dated December 12, 2008, among Logic Express Limited, Chongqing Dalin Biologic Technologies Co., Ltd., and certain shareholders of Chongqing Dalin Biologic Technologies Co., Ltd. (English Translation) (incorporated by reference to exhibit 10.4 of the current report of Form 8-K, filed by the Company on December 18, 2008)    
 
      10.25.   
       
      Equity Transfer Agreement, between Shandong Taibang Biological Products Co., Ltd. and Mr. Fan Qingchun, dated October 10, 2008 (incorporated by reference to Exhibit 10.1 of the current report on Form 8-K, filed by the Company on October 16, 2008)    
 
      10.26.   
       
      Joint Venture and Cooperation Agreement between Mr. Fan Qingchun, Shandong Taibang Biological Products Co., Ltd. and Shaanxi Power Construction Corporation, dated September 12, 2008 (incorporated by reference to Exhibit 10.2 of the current report on Form 8-K, filed by the Company on October 16, 2008)    
 
      10.27.   
       
      Agreement on Equity Transfer, Acquisition, Joint Venture and Cooperation, among Shandong Taibang Biological Products Co., Ltd., Shaanxi Power Construction Corporation and Mr. Fan Qingchun, dated September 12, 2008 (incorporated by reference to Exhibit 10.3 of the current report on Form 8-K, filed by the Company on October 16, 2008)    
 
      10.28.   
       
      (Shareholder) Agreement among Shandong Taibang Biological Products Co., Ltd., Logic Express Limited and Biological Institute, dated September 12, 2008 (incorporated by reference to Exhibit 10.4 of the current report on Form 8-K, filed by the Company on October 16, 2008)    
 
      10.29.   
       
      Trademark Licensing Agreement, dated as of February 27, 2007 (English Translation) (incorporated by reference to Exhibit 10.17 of the registration statement on Form SB-2/A, filed by the Company on December 3, 2007)    
 
      10.30.   
       
      Loan Agreement, dated as of November 30, 2006, among Shandong Taibang and the Shandong Institute and Logic Express (English Translation) (incorporated by reference to Exhibit 10.18 of the registration statement on Form SB-2/A, filed by the Company on December 3, 2007)    
 
      10.31.   
       
      Supplementary Agreement, dated as of September 1, 2007, among Shandong Taibang Biological Products Co., Ltd., the Shandong Institute and Logic Express Limited (English Translation) (incorporated by reference to Exhibit 10.19 of the registration statement on Form SB-2/A, filed by the Company on December 3, 2007)    
 
      10.32.   
       
      Form of Bank of Communications Loan Contract, among Shandong Taibang and the Taian Branch of the Bank of Communications (English Translation) (incorporated by reference to Exhibit 10.20 of the registration statement on Form SB-2/A, filed by the Company on December 3, 2007)    
 
      10.33.   
       
      China Bank of Communications Loan Contract, dated October 28, 2008, between Shandong Taibang Biological Products Co. Ltd. and Bank of Communications, Taian Branch (English Translation) (incorporated by reference to Exhibit 10.1 of the current report on Form 8-K, filed by the Company on November 3, 2008)    

11   

*Previously filed with our Annual Report
on Form 10-K for the year ended December 31, 2008, as filed on March 31, 2009. 

 **Previously furnished with our Annual
Report on Form 10-K for the year ended December 31, 2008, as filed on March 31, 2009. 

 ***Filed herewith. 

12   

<EX-31.1>
 2
 v451981_ex31-1.htm
 EXHIBIT 31.1

EXHIBIT 31.1   

CERTIFICATIONS  

I, David (Xiaoying) Gao, certify that: 

1.  I have reviewed this Amendment No.1 to the Annual Report on Form 10-K of China Biologic Products, Inc.; and   

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report.   

Date: November 2, 2016 

/s/ David (Xiaoying) Gao  

David (Xiaoying) Gao  

Chief Executive Officer   

(Principal Executive Officer)    

</EX-31.1>

<EX-31.2>
 3
 v451981_ex31-2.htm
 EXHIBIT 31.2

EXHIBIT 31.2   

CERTIFICATIONS  

I, Ming Yang, certify that: 

1.  I have reviewed this Amendment No.1 to the Annual Report on Form 10-K of China Biologic Products, Inc.; and   

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report.   

Date: November 2, 2016 

/s/ Ming Yang  

Ming Yang  

Chief Financial Officer   

(Principal Financial and Accounting Officer)    

</EX-31.2>

